Discovery services company Domainex has appointed Timo Veromaa as Executive Chair.
Veromaa was President and CEO of Biotie Therapies Corporation for over 11 years until its acquisition by Acorda Therapeutics in 2016.
During this period he achieved significant growth in the company, including the launch of Selincro (an opioid antagonist), and a listing on the US Nasdaq stock exchange.
During his earlier career he was a Medical Director of Schering, Finland; Senior Scientist and Project Director at Collagen Corporation; and a Postdoctoral Fellow at Stanford University in California.
He is a medical doctor with a PhD in immunology from the University of Turku, Finland.
Veromaa will have a pivotal role in leading the organisation through a continuing period of growth and investment.
In the past 12 months, Domainex has doubled its laboratory space with a move to the Domainex Medicines Research Centre on the Chesterford Research Park near Cambridge, and has expanded its international team of scientists by more than 50%.
“Domainex enjoys an outstanding reputation for scientific excellence in drug discovery. I believe we are in a strong position to build on our capabilities to serve our global client base,” said Veromaa.
